Black Diamond Therapeutics, Inc.
BDTXNASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $96.95M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.60$4.94
- Volume (live)
- -
- Avg. volume (3M)
- 784.09K
Black Diamond Therapeutics (BDTX) Stock Price & Financial Analysis
Black Diamond Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.67 - $1.90 |
|---|---|
| 52-Week High | $4.94 |
| 52-Week Low | $1.60 |
| Open | $1.89 |
| Volume (last close) | 862.91K |
| Average Volume (3M) | 784.09K |
| 50-Day MA | $1.98 |
|---|---|
| 200-Day MA | $2.23 |
| 1-Year Change | −46.39% |
| Market Cap | 96.95M |
|---|---|
| Shares Outstanding | 57.37M |
| Price to Book (P/B) | 1.01 |
| EV/EBITDA | -2.64 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Black Diamond Therapeutics at a Glance
As of the Oct 26, 2026 close, Black Diamond Therapeutics (BDTX) has a market capitalization of $96.95M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $19.19M in cash and securities against $16.97M of debt, a net cash position of $2.22M.
Black Diamond Therapeutics does not currently pay a dividend.
The share price is down 46.4% over the past year. At $1.69 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $1.60 to $4.94, below its 200-day moving average of $2.23.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $10.33, 511.2% above the Oct 26, 2026 close.
Frequently Asked Questions About Black Diamond Therapeutics
What is the current stock price for BDTX?
As of the Oct 26, 2026 close, BDTX stock trades at $1.69. The 52-week range is $1.60–$4.94, with a day range of $1.67–$1.90.
What is the P/E ratio for BDTX?
The P/E ratio (Price-to-Earnings) for BDTX is shown in the Key Statistics section. This valuation metric helps compare Black Diamond Therapeutics, Inc. to industry peers.
Does BDTX pay dividends?
Black Diamond Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BDTX?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for BDTX is Buy. The average 12-month price target is $10.33, a 511.2% upside from the Oct 26, 2026 close of $1.69.
What is the market cap of BDTX?
As of the Oct 26, 2026 close, Black Diamond Therapeutics's market capitalization is $97.0M, classifying it as a micro-cap company. Black Diamond Therapeutics operates in the Healthcare sector within the Biotechnology industry.